Merck, Inc.
🇺🇸United States
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Phase 2
Not yet recruiting
- Conditions
- Malignant Neoplasm
- Interventions
- Drug: Megestrol acetate/Medroxyprogesterone acetateDrug: Fludrocortisone/ Fludrocortisone acetateDrug: Dexamethasone/Dexamethasone acetateDrug: Rescue Medications
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 250
- Registration Number
- NCT06979596
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3
Not yet recruiting
- Conditions
- Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2400
- Registration Number
- NCT06966700
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Phase 2
Not yet recruiting
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06961006
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Phase 2
Not yet recruiting
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 147
- Registration Number
- NCT06956235
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Phase 3
Not yet recruiting
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1123
- Registration Number
- NCT06952504
A Study to Evaluate the Effect of Formulation and Food on MK-1084 in Healthy Adult Participants (MK-1084-011)
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Drug: MK-1084 OCTDrug: MK-1084 FCT
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 52
- Registration Number
- NCT06942741
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT06941272
A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Biological: Sotatercept Autoinjector
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT06930664
- Locations
- 🇺🇸
Anaheim Clinical Trials ( Site 0007), Anaheim, California, United States
🇺🇸Advanced Pharma CR, LLC ( Site 0005), Miami, Florida, United States
🇺🇸QPS-MRA, LLC ( Site 0004), South Miami, Florida, United States
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
Phase 2
Recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06925750
- Locations
- 🇬🇧
Hammersmith Hospital ( Site 1801), London, London, City Of, United Kingdom
🇬🇧Golden Jubilee National Hospital ( Site 1800), Glasgow City, Scotland, United Kingdom
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Phase 3
Recruiting
- Conditions
- Prostate CancerProstatic Neoplasms
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1440
- Registration Number
- NCT06925737
- Locations
- 🇺🇸
St. Vincent Frontier Cancer Center-Research ( Site 0037), Billings, Montana, United States
🇺🇸Blue Ridge Cancer Care ( Site 0024), Roanoke, Virginia, United States
🇮🇱Rambam Health Care Campus ( Site 0462), Haifa, Israel
© Copyright 2025. All Rights Reserved by MedPath